https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=70&w=70

msapplication-square70x70logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=150&w=150

msapplication-square150x150logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=310&w=310

msapplication-square310x310logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=150&w=310

msapplication-square310x150logo

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our <a href="https://www.wsgr.com/en/privacy-policy.html" target="_blank">privacy policy</a>.

<p>On November 15, 2021, Podium, a communication and payments platform for local businesses, announced it has raised $201 million in Series D funding, led by YC Continuity with participation from Durable Capital Partners, Arpex Capital, Accel, Album VC, IVP, Sapphire Ventures, Summit Partners, and Sorenson Capital. This latest round brings the company's valuation to over $3 billion. Wilson Sonsini Goodrich &amp; Rosati represented Podium in the transaction.</p>

<p>Additional funding will support Podium's expansion to reach more local businesses all over the world as well as deeper investments to build out their technologies. This includes supporting everything a local business may need to collect payments, manage all their communications with consumers, and create more personalized and effective marketing campaigns that drive conversations and revenue.</p>

<p>The Wilson Sonsini team that represented Podium in the transaction includes<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1046" title="Robert G. Day" href="https://www.wsgr.com/en/people/robert-g-day.html" data-rubyapp-reference="content::1046">Bob Day</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1046 rubycontent-page-link rubycontent-page-1146" title="Rezwan D. Pavri" href="https://www.wsgr.com/en/people/rezwan-d-pavri.html" data-rubyapp-reference="content::1146">Rezwan Pavri</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1046 rubycontent-page-link rubycontent-page-1146 rubycontent-page-link rubycontent-page-1212" title="Andrew T. Hill" href="https://www.wsgr.com/en/people/andrew-t-hill.html" data-rubyapp-reference="content::1212">Andy Hill</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1046 rubycontent-page-link rubycontent-page-1146 rubycontent-page-link rubycontent-page-1212 rubycontent-page-link rubycontent-page-1514" title="Lester Ang" href="https://www.wsgr.com/en/people/lester-ang.html" data-rubyapp-reference="content::1514">Lester Ang</a>, and<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1046 rubycontent-page-link rubycontent-page-1146 rubycontent-page-link rubycontent-page-1212 rubycontent-page-link rubycontent-page-1514 rubycontent-page-link rubycontent-page-5848" title="Jacqueline Jung" href="https://www.wsgr.com/en/people/jacqueline-jung.html" data-rubyapp-reference="content::5848">Jacqueline Jung</a>.</p>

<p>For more information, please see Podium's<span>&nbsp;</span><a rel="noopener" href="https://www.prnewswire.com/news-releases/podium-raises-201m-in-series-d-funding-to-accelerate-the-digital-evolution-for-local-businesses-301424024.html" target="_blank">press release</a>.</p>


Wilson Sonsini Advises Podium on $201 Million Series D Round

<div class="sticky-footer__content--897fd705 default__pageContentWrapper--4206be45">
  <div class="styles__contentContainer--d57bde7c">
    <div class="bg-white u-content-below-header">
      <div class="grid__baseGrid--1cdd58ce grid__withMargins--b42113c3">
        <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false ">
          <div class="column__l-xs-6-6--c9a9ad7f  column__l-sm-9-12--f45fdef1  column__l-lg-9-12--5cc60621  column__l-lgPaddingLeft-2-12--2746759a paddingTopLarge">
            <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false styles__mainContentContainer--84d6f609">
              <div class="column__l-sm-8-9--7856db3d  column__l-lg-8-9--7f175e19  column__l-xs-6-6--c9a9ad7f">
                <div class="styles__mainContent--45c82986 color-navy">
                  <div class="rte">
                    <p>On November 11, 2021, Ignis Therapeutics, a biopharmaceutical company focusing on the central nervous system (CNS) incubated by 6 Dimensions Capital (6D), a Shanghai-based global investment firm, announced its&nbsp;$180 million Series A financing led by 6D. To date, the transaction represents the&nbsp;largest Series A financing in&nbsp;the biopharmaceutical&nbsp;sector in China&nbsp;in 2021. The financing includes co-investor participation by&nbsp;Ruentex Group,&nbsp;KB Investment,&nbsp;WTT investment,&nbsp;Mubadala Investment Company,&nbsp;HBM Healthcare Investments, and Goldman Sachs.</p>
                    <p>As&nbsp;part of the&nbsp;transaction, Ignis Therapeutics enters into a&nbsp;long-term strategic&nbsp;license agreement with SK Biopharmaceuticals (SKBP) under which SKBP out-licenses six of its clinical compounds, including U.S. FDA-approved cenobamate and solriamfetol, to Ignis Therapeutics, for development and commercialization. The proceeds from the Series A round of financing will be used for development and commercialization of these products.&nbsp;</p>
                    <p>Wilson Sonsini Goodrich &amp; Rosati represented&nbsp;6D and&nbsp;Ignis Therapeutics&nbsp;in this transaction. The team includes:</p>
                    <p><strong>Corporate<br /></strong><a class="rubycontent-page-link rubycontent-page-1275" title="Weiheng Chen" href="https://www.wsgr.com/en/people/weiheng-chen.html" data-rubyapp-reference="content::1275">Weiheng Chen</a>, Partner<br /><a class="rubycontent-page-link rubycontent-page-1276" title="Jie Zhu" href="https://www.wsgr.com/en/people/jie-zhu.html" data-rubyapp-reference="content::1276">Jie Zhu</a>, Partner<br /><a class="rubycontent-page-link rubycontent-page-1450" title="Can Yin" href="https://www.wsgr.com/en/people/can-yin.html" data-rubyapp-reference="content::1450">Can Yin</a>, Of Counsel<br /><a class="rubycontent-page-link rubycontent-page-170827" title="Xuchao Dong" href="https://www.wsgr.com/en/people/xuchao-dong.html" data-rubyapp-reference="content::170827">Xuchao Dong</a>, Of Counsel<br /><a class="rubycontent-page-link rubycontent-page-206081" title="Yushen Liu" href="https://www.wsgr.com/en/people/yushen-liu.html" data-rubyapp-reference="content::206081">Yushen Liu</a>, Associate</p>
                    <p><strong>Patents and Innovations<br /></strong><a class="rubycontent-page-link rubycontent-page-1445" title="Chi-Fei Wang" href="https://www.wsgr.com/en/people/chi-fei-wang.html" data-rubyapp-reference="content::1445">Chi-Fei Wang</a>, Of Counsel<br /><a class="rubycontent-page-link rubycontent-page-1347" title="Richard Wang" href="https://www.wsgr.com/en/people/richard-wang.html" data-rubyapp-reference="content::1347">Richard Wang</a>, Of Counsel</p>
                    <p>For more information, please see&nbsp;SKBP&rsquo;s&nbsp;<a href="https://www.skbp.com/eng/news/view.do?boardCode=BDCD0002&amp;boardSeq=539&amp;currentPage=1&amp;search=">press release</a>.</p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>


Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

<div class="sticky-footer__content--897fd705 default__pageContentWrapper--4206be45">
  <div class="styles__contentContainer--d57bde7c">
    <div class="bg-white u-content-below-header">
      <div class="grid__baseGrid--1cdd58ce grid__withMargins--b42113c3">
        <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false ">
          <div class="column__l-xs-6-6--c9a9ad7f  column__l-sm-9-12--f45fdef1  column__l-lg-9-12--5cc60621  column__l-lgPaddingLeft-2-12--2746759a paddingTopLarge">
            <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false styles__mainContentContainer--84d6f609">
              <div class="column__l-sm-8-9--7856db3d  column__l-lg-8-9--7f175e19  column__l-xs-6-6--c9a9ad7f">
                <div class="styles__mainContent--45c82986 color-navy">
                  <div class="rte">
                    <p>On November 3, 2021, Merge, an integrations platform that focuses on B2B use cases, announced that it has raised a $15 million Series A funding round led by Addition, with participation from existing investor NEA and a number of angel investors. Wilson Sonsini Goodrich &amp; Rosati advised Merge on the transaction.<br /><br />According to Merge co-founder Gil Feig, the fundraise allows the company to commit to growing not just its product and team, but its partnerships, a critical part of the business. &ldquo;With this round, we&rsquo;re continuing on our mission to revolutionize how every B2B company approaches its integrations strategy,&rdquo; he wrote. In addition to the Series A funding, Merge announced partnerships with HR provider BambooHR and application tracking system Lever.<br /><br />When Merge announced its seed funding with NEA in May 2021, there were 100 companies on its platform; that figure is now more than 600, including several public companies. The company has released several product features since then, including better logs, enhanced webhooks, CSV upload, SAML SSO, and a single-tenant offering; built out integrations for platforms like Oracle Taleo, Jobvite, and Workday HRIS; and grown its team to 20 people.<br /><br />The Wilson Sonsini team that advised Merge on the transaction included<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/seth-j-helfgott.html">Seth Helfgott</a>,<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/robert-d-broderick.html">Rob Broderick</a>,<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/daniel-xo.html">Daniel Xo</a>,<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/adam-l-shevell.html">Adam Shevell</a>, and<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/matt-staples.html">Matt Staples</a>.<br /><br />For more information, please see the<span>&nbsp;</span><a rel="noopener" href="https://www.merge.dev/blog/company/announcing-our-$15-million-series-a-and-expanded-partnerships" target="_blank">announcement</a><span>&nbsp;</span>on Merge&rsquo;s blog and this<span>&nbsp;</span><a rel="noopener" href="https://techcrunch.com/2021/11/03/merge-raises-15m-series-a-for-its-b2b-integrations-platform/?guccounter=1" target="_blank">TechCrunch article</a>.</p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>


Wilson Sonsini Advises Merge on $15 Million Series A Funding

<div class="sticky-footer__content--897fd705 default__pageContentWrapper--4206be45">
  <div class="styles__contentContainer--d57bde7c">
    <div class="bg-white u-content-below-header">
      <div class="grid__baseGrid--1cdd58ce grid__withMargins--b42113c3">
        <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false ">
          <div class="column__l-xs-6-6--c9a9ad7f  column__l-sm-9-12--f45fdef1  column__l-lg-9-12--5cc60621  column__l-lgPaddingLeft-2-12--2746759a paddingTopLarge">
            <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false styles__mainContentContainer--84d6f609">
              <div class="column__l-sm-8-9--7856db3d  column__l-lg-8-9--7f175e19  column__l-xs-6-6--c9a9ad7f">
                <div class="styles__mainContent--45c82986 color-navy">
                  <div class="rte">
                    <p>On November 2, 2021, Cambridge Epigenetix, a life sciences tools and technology company revolutionizing genome sequencing, announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital, and Sequoia. Wilson Sonsini Goodrich &amp; Rosati advised Cambridge Epigenetix on IP matters related to the transaction.</p>
                    <p>Proceeds from the financing will be used to commercialize the company&rsquo;s proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA. The technology has been validated by leading genomic research institutions of which several, including Professor Dennis Lo of The Chinese University of Hong Kong, and Professor Wolf Reik of the Babraham Institute, have continued using the technology through early access programs.<br /><br />The Wilson Sonsini team that advised Cambridge Epigenetix on IP matters related to the transaction includes<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1136" title="Vern Norviel" href="https://www.wsgr.com/en/people/vern-norviel.html" data-rubyapp-reference="content::1136">Vern Norviel</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1136 rubycontent-page-link rubycontent-page-1866" title="Srividya Chandramouli" href="https://www.wsgr.com/en/people/srividya-chandramouli.html" data-rubyapp-reference="content::1866">Srividya Chandramouli</a>, and<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1136 rubycontent-page-link rubycontent-page-1866 rubycontent-page-link rubycontent-page-1331" title="Adam J. Cole" href="https://www.wsgr.com/en/people/adam-j-cole.html" data-rubyapp-reference="content::1331">Adam Cole</a>.</p>
                    <p>For more information, please see Cambridge Epigenetix&rsquo;s<span>&nbsp;</span><a rel="noopener" href="https://www.globenewswire.com/news-release/2021/11/02/2325233/0/en/Cambridge-Epigenetix-Raises-88-Million-Series-D-Financing-to-Advance-Best-in-Class-DNA-Sequencing-Technology-Platform.html" target="_blank">press release</a>.</p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>


Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D

<h2><em>Justice<span>&nbsp;</span></em><em>Deno Himonas, Renowned Jurist and Legal Innovator,<span>&nbsp;</span></em><em>to Join Office Upon His Retirement</em></h2>

<h2><em>Wilson Sonsini Enters Market to Serve Client Base, Emerging Companies in<span>&nbsp;</span></em><em>Utah&rsquo;s Thriving Business Climate</em></h2>

<p><strong>Contact:<br /></strong>Kelsey Dellovo<br />Baretz+Brunelle<br />339.223.0961 Mobile<br /><a href="mailto:kdellovo@baretzbrunelle.com">kdellovo@baretzbrunelle.com</a></p>

<p><strong>PALO ALTO, CA<span>&nbsp;</span></strong><strong>(</strong><strong>November 2, 2021</strong><strong>) &ndash;</strong><span>&nbsp;</span>Wilson Sonsini Goodrich &amp; Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that the firm is opening an office in Salt Lake City, which Utah Supreme Court Justice<span>&nbsp;</span><strong>Deno Himonas</strong><span>&nbsp;</span>will join upon his retirement from the bench in March 2022. In the Salt Lake City office, he will join Wilson Sonsini partners<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/marc-porter.html"><strong>Marc Porter</strong></a>, who comes to the firm from Holland &amp; Hart, and<span>&nbsp;</span><a href="https://www.wsgr.com/en/people/matt-l-squires.html"><strong>Matt Squires</strong></a>, most recently of the firm&rsquo;s Seattle office.</p>

<p>&ldquo;With today&rsquo;s announcement, we enhance our longstanding client relationships in the region, recognize Salt Lake City for the vibrant market it has become for emerging technology and life sciences companies, and we look forward to adding an invaluable asset to the firm in the person of Justice Himonas,&rdquo; said<span>&nbsp;</span><strong>Doug Clark</strong>, managing partner of Wilson Sonsini. &ldquo;Our expansion into Salt Lake City will allow us to better serve Utah&rsquo;s innovative companies, as well as the investors and institutions that support them.&rdquo;</p>

<p>Wilson Sonsini has advised more venture capital firms on Utah-related deals and more Utah-based issuers on IPOs than any other firm since 2016, ranking first in each category by a substantial margin. The firm ranks fourth among law firms in advising on Utah-related mergers and acquisitions in the same period. &ldquo;We have been actively advising on capital markets, venture financing, M&amp;A, and other transactions in the Utah business community for many years,&rdquo; said<span>&nbsp;</span><strong>Allison Spinner</strong>, the leader of Wilson Sonsini&rsquo;s corporate department. &ldquo;The addition of Marc Porter and relocation of Matt Squires cements our long-term presence in Salt Lake City and makes it even easier for us to address the sophisticated needs of clients in the growing Utah market.&rdquo;</p>

<p>Since 2019, Wilson Sonsini has had a physical presence in Utah through SixFifty, a software subsidiary that develops automated tools that make legal processes&mdash;like drafting employee handbooks&mdash;efficient and affordable. &ldquo;The firm has recognized Utah as a site of innovation, and the opening of a firm office here just confirms that,&rdquo; said<span>&nbsp;</span><strong>Kimball Dean Parker</strong>, the CEO of SixFifty and the director of LawX, a legal design lab at Brigham Young University Law School. &ldquo;It&rsquo;s fitting that the Utah office of Wilson Sonsini will include Justice Himonas, one of the most forward-thinking members of our judiciary.&rdquo;</p>

<p>Justice Himonas will join Wilson Sonsini&rsquo;s litigation and appellate practices and advise companies on complex governance and regulatory issues. He served as a trial court judge in Utah for 10 years before his appointment to the Utah Supreme Court in 2015. Throughout his legal career, he has concerned himself with issues relating to the access and affordability of civil justice in the U.S. court system. Justice Himonas has received widespread acclaim, including distinction by the American Bar Association as a &ldquo;Legal Rebel,&rdquo; for his work with Utah attorney John Lund to establish Utah&rsquo;s Office of Legal Services Innovation and a regulatory &ldquo;sandbox&rdquo; allowing entities to explore new ways of delivering legal services. More than 25 innovations are being piloted in the sandbox.</p>

<p>Porter has developed a leading corporate practice for technology, consumer products, and life sciences companies in Utah, where he has spent much of his professional career, and beyond. He executes a substantial volume of financings and liquidity events each year for early- to late-stage private companies as well as venture capital firms. Before entering private practice, he served a clerkship on the U.S. Court of Appeals for the 10th Circuit and graduated from Brigham Young University Law School.</p>

<p>Squires, a Utah native and head of the firm&rsquo;s Latin America practice, brings significant experience with both domestic and cross-border venture financings, mergers and acquisitions, and public and private capital markets transactions for clients in technology, software, logistics, clean energy, and other industries.</p>

<p>&ldquo;Utah continues its rapid momentum as a great place to do business, particularly for technology companies. Wilson Sonsini&rsquo;s presence not only validates that fact, but makes it truer than ever,&rdquo; said<span>&nbsp;</span><strong>Josh James</strong>, technology visionary and founder and CEO of Domo, a Wilson Sonsini client. &ldquo;The firm is already a critical advisor to many local companies and executives, including me, and with this move, it has set the table for even greater things to come in Utah.&rdquo;</p>

<p><em>About Wilson Sonsini Goodrich &amp; Rosati</em><br />For more than 60 years, Wilson Sonsini&rsquo;s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has offices in Austin; Beijing; Boston; Brussels; Hong Kong; London; Los Angeles; New York; Palo Alto; San Diego; San Francisco; Seattle; Shanghai; Washington, D.C.; and Wilmington, DE. For more information, please visit<span>&nbsp;</span><a href="https://www.wsgr.com/">www.wsgr.com</a>.</p>


Press Releases

Wilson Sonsini Launches Salt Lake City Office with Retiring Utah Supreme Court Justice, Veteran Corporate Team

<div class="sticky-footer__content--897fd705 default__pageContentWrapper--4206be45">
  <div class="styles__contentContainer--d57bde7c">
    <div class="bg-white u-content-below-header">
      <div class="grid__baseGrid--1cdd58ce grid__withMargins--b42113c3">
        <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false ">
          <div class="column__l-xs-6-6--c9a9ad7f  column__l-sm-9-12--f45fdef1  column__l-lg-9-12--5cc60621  column__l-lgPaddingLeft-2-12--2746759a paddingTopLarge">
            <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false styles__mainContentContainer--84d6f609">
              <div class="column__l-sm-8-9--7856db3d  column__l-lg-8-9--7f175e19  column__l-xs-6-6--c9a9ad7f">
                <div class="styles__mainContent--45c82986 color-navy">
                  <div class="rte">
                    <p>On October 27, 2021, Arcaea, a company launched on the Ginkgo Bioworks platform, announced its $78 million Series A to build a new, regenerative future for the beauty industry through expressive biology&mdash;where biology is used as a creative tool for self-expression. Arcaea, formerly known as Kalo Ingredients, LLC, &nbsp;will grow new ingredients and product experiences for beauty by leveraging technology such as DNA sequencing, biological engineering, and fermentation to activate unique storytelling. Wilson Sonsini Goodrich &amp; Rosati advised Arcaea on intellectual property, patent, licensing and contracts, including its spinout from Gingko Bioworks.<br /><br />The Series A funding comes from a consortium of strategic and financial investors including Cascade Investment L.L.C., Viking Global, CHANEL, Givaudan, and Wittington Ventures. The financing will enable Arcaea to initiate multiple technical programs across key categories in beauty to develop a pipeline of ingredients and brand launches and create a world of previously unimaginable possibilities in beauty, such as: a fragrance that no one on earth has ever smelled before; proteins that can memorize hair styles; contouring through skincare and not just makeup; and biological filters that protect skin from the elements.</p>
                    <p>The Wilson Sonsini team that advised Arcaea on the transaction includes:<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1931" title="Austin A. Rutherford" href="https://www.wsgr.com/en/people/austin-a-rutherford.html" data-rubyapp-reference="content::1931">Austin Rutherford</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1931 rubycontent-page-link rubycontent-page-1604" title="Stephanie S. Dusaban Gonzales" href="https://www.wsgr.com/en/people/stephanie-s-dusaban-gonzales.html" data-rubyapp-reference="content::1604">Stephanie Dusaban Gonzales</a>, and<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1931 rubycontent-page-link rubycontent-page-1604" href="https://www.wsgr.com/en/people/matthew-j-bresnahan.html">Matt Bresnahan</a>.</p>
                    <p>For more information, please see Arcaea&rsquo;s<span>&nbsp;</span><a rel="noopener" href="https://www.prnewswire.com/news-releases/arcaea-a-company-launched-on-the-ginkgo-bioworks-platform-announces-78m-series-a-to-build-a-new-foundation-for-the-beauty-industry-through-expressive-biology-301409534.html" target="_blank">press release</a>.</p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>


Wilson Sonsini Advises Arcaea, Inc. on $78 Million Series A Financing

<div class="sticky-footer__content--897fd705 default__pageContentWrapper--4206be45">
  <div class="styles__contentContainer--d57bde7c">
    <div class="bg-white u-content-below-header">
      <div class="grid__baseGrid--1cdd58ce grid__withMargins--b42113c3">
        <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false ">
          <div class="column__l-xs-6-6--c9a9ad7f  column__l-sm-9-12--f45fdef1  column__l-lg-9-12--5cc60621  column__l-lgPaddingLeft-2-12--2746759a paddingTopLarge">
            <div class="row__row--07cf1d98 false row__columnWrap--1417cfa6  false styles__mainContentContainer--84d6f609">
              <div class="column__l-sm-8-9--7856db3d  column__l-lg-8-9--7f175e19  column__l-xs-6-6--c9a9ad7f">
                <div class="styles__mainContent--45c82986 color-navy">
                  <div class="rte">
                    <p>On October 12, 2021, CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. Wilson Sonsini Goodrich &amp; Rosati represented General Atlantic on the transaction.</p>
                    <p>The proceeds from the round will support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism, and chronic kidney disease. The new funding will enable completion of the ongoing brigHTN Phase 2 clinical trial in patients with resistant hypertension as well as the ongoing Phase 2 Spark trial in hypertensive individuals with primary aldosteronism; in addition, it will support initiation of two new trials, a Phase 2 clinical trial (HALO) in patients with uncontrolled hypertension and a study of CIN-107&rsquo;s impact on blood pressure and kidney function in patients with chronic kidney disease (CKD).</p>
                    <p>The Wilson Sonsini team that advised General Atlantic on the transaction include<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1155" title="John M. Brust" href="https://www.wsgr.com/en/people/john-m-brust.html" data-rubyapp-reference="content::1155">John Brust</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1155 rubycontent-page-link rubycontent-page-1077" title="Lowell Segal" href="https://www.wsgr.com/en/people/lowell-segal.html" data-rubyapp-reference="content::1077">Lowell Segal</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1155 rubycontent-page-link rubycontent-page-1077 rubycontent-page-link rubycontent-page-1149" title="Michael Hostetler" href="https://www.wsgr.com/en/people/michael-hostetler.html" data-rubyapp-reference="content::1149">Mike Hostetler</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1155 rubycontent-page-link rubycontent-page-1077 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1462" title="Julia L. Minitti" href="https://www.wsgr.com/en/people/julia-l-minitti.html" data-rubyapp-reference="content::1462">Julia Minitti</a>,<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1155 rubycontent-page-link rubycontent-page-1077 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1462 rubycontent-page-link rubycontent-page-17978" title="Luis G. Perla" href="https://www.wsgr.com/en/people/luis-perla.html" data-rubyapp-reference="content::17978">Luis Perla</a>, and<span>&nbsp;</span><a class="rubycontent-page-link rubycontent-page-1656" title="Amanda K. Creedon" href="https://www.wsgr.com/en/people/amanda-k-creedon.html" data-rubyapp-reference="content::1656">Amanda Creedon</a>.</p>
                    <p>For more information, please see General Atlantic&rsquo;s<span>&nbsp;</span><a rel="noopener" href="https://www.generalatlantic.com/media-article/cincor-pharma-raises-143-million-in-series-b-financing/" target="_blank">press release</a>.</p>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>


Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing

<p>On October, 20, 2021, North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund, Alexandria and Gaingels. Wilson Sonsini Goodrich &amp; Rosati represented Novo Holdings on the transaction.</p>

<p>Investment partners for the round were selected based in part on alignment with BIOMILQ&rsquo;s core set of values: having female leadership within their fund, having a portfolio of diverse founders, and having an internal mandate for positive impact in the world. Utilizing proprietary technology, BIOMILQ announced capability for producing human milk outside of the body this year. The additional funds from the fundraise will accelerate their process development and optimization, enabling full commercialization over the next 4 years.</p>

<p>The Wilson Sonsini team that represented Novo Holdings on the transaction includes:</p>

<p><strong>Corporate</strong>:<br /><a class="rubycontent-page-link rubycontent-page-1179" title="Dan R. Koeppen" href="https://www.wsgr.com/en/people/dan-r-koeppen.html" data-rubyapp-reference="content::1179">Dan Koeppen</a><br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441" title="Kassandra K. Castillo" href="https://www.wsgr.com/en/people/kassandra-k-castillo.html" data-rubyapp-reference="content::1441">Kassandra Castillo</a><br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980" title="Bridget Balisy" href="https://www.wsgr.com/en/people/bridget-balisy.html" data-rubyapp-reference="content::17980">Bridget Balisy</a></p>

<p><strong>Intellectual</strong><span>&nbsp;</span><strong>Property</strong>:<br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980 rubycontent-page-link rubycontent-page-1149" title="Michael Hostetler" href="https://www.wsgr.com/en/people/michael-hostetler.html" data-rubyapp-reference="content::1149">Mike Hostetler</a><br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1274" title="Deborah M. Smith" href="https://www.wsgr.com/en/people/deborah-m-smith.html" data-rubyapp-reference="content::1274">Deborah Smith</a><br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1274 rubycontent-page-link rubycontent-page-1604" title="Stephanie S. Dusaban Gonzales" href="https://www.wsgr.com/en/people/stephanie-s-dusaban-gonzales.html" data-rubyapp-reference="content::1604">Stephanie Dusaban Gonzales</a></p>

<p><strong>National</strong><span>&nbsp;</span><strong>Security</strong>:<br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1274 rubycontent-page-link rubycontent-page-1604 rubycontent-page-link rubycontent-page-1722" title="Stephen R. Heifetz" href="https://www.wsgr.com/en/people/stephen-r-heifetz.html" data-rubyapp-reference="content::1722">Stephen Heifetz</a><br /><a class="rubycontent-page-link rubycontent-page-1179 rubycontent-page-link rubycontent-page-1441 rubycontent-page-link rubycontent-page-17980 rubycontent-page-link rubycontent-page-1149 rubycontent-page-link rubycontent-page-1274 rubycontent-page-link rubycontent-page-1604 rubycontent-page-link rubycontent-page-1722 rubycontent-page-link rubycontent-page-1881" title="Jonathan R. Davey" href="https://www.wsgr.com/en/people/jonathan-r-davey.html" data-rubyapp-reference="content::1881">Jonathan Davey</a></p>

<p>For more information, please see BIOMILQ&rsquo;s<span>&nbsp;</span><a rel="noopener" href="https://biomilq.medium.com/21million-77f2bd99097d" target="_blank">press release</a></p>


all insights

we want to share
with you

Wilson Sonsini Advises Podium on $201 Million Series D Round

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Wilson Sonsini Advises Merge on $15 Million Series A Funding

Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D

Wilson Sonsini Launches Salt Lake City Office with Retiring Utah Supreme Court Justice, Veteran Corporate Team

Wilson Sonsini Advises Arcaea, Inc. on $78 Million Series A Financing

Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing

Wilson Sonsini Represents Novo Holdings on BIOMILQ, Inc.’s $21 Million Series A Financing

all insights.css-1mrua6o{margin-top:8px;margin-bottom:0;}.css-1ic8ug3{box-sizing:border-box;margin:0;min-width:0;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-top:8px;margin-bottom:0;}

.css-vurnku{box-sizing:border-box;margin:0;min-width:0;}we want to sharewith you

Wilson Sonsini Advises Podium on $201 Million Series D Round

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Wilson Sonsini Advises Merge on $15 Million Series A Funding

Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D

Wilson Sonsini Launches Salt Lake City Office with Retiring Utah Supreme Court Justice, Veteran Corporate Team

Wilson Sonsini Advises Arcaea, Inc. on $78 Million Series A Financing

Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing

Wilson Sonsini Represents Novo Holdings on BIOMILQ, Inc.’s $21 Million Series A Financing

all insights

we want to share
with you